GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients

Acta Oncol. 2013 May;52(4):871-4. doi: 10.3109/0284186X.2012.707787. Epub 2012 Aug 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Carcinoma / drug therapy
  • Carcinoma / epidemiology
  • Carcinoma / genetics*
  • Extracellular Matrix Proteins / genetics*
  • Female
  • GPI-Linked Proteins / genetics
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Humans
  • Nervous System Diseases / chemically induced*
  • Nervous System Diseases / genetics*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / epidemiology
  • Ovarian Neoplasms / genetics*
  • Paclitaxel / adverse effects*
  • Paclitaxel / therapeutic use
  • Polymorphism, Single Nucleotide / physiology
  • Reproducibility of Results
  • Retrospective Studies
  • Scandinavian and Nordic Countries / epidemiology
  • Validation Studies as Topic

Substances

  • Antineoplastic Agents, Phytogenic
  • Extracellular Matrix Proteins
  • GPI-Linked Proteins
  • TECTA protein, human
  • Paclitaxel